-
公开(公告)号:US20210177753A1
公开(公告)日:2021-06-17
申请号:US16761337
申请日:2018-11-06
申请人: PHARMATHEN S.A.
发明人: Evangelos KARAVAS , Efthymios KOUTRIS , Vasiliki SAMARA , Ioanna KOUTRI , Anastasia KALASKANI , Andreas KAKOURIS , Rumit Rajivbhai SHAH
IPC分类号: A61K9/08 , A61K31/542 , A61K31/498 , A61K9/00 , A61K47/02 , A61K47/10 , A61K47/32 , A61K47/34
摘要: The present invention relates to an ophthalmic aqueous composition for the decrease of intraocular pressure in patients with ocular hypertension or open angle glaucoma containing a combination of Brinzolamide and Brimonidine and a method for preparation thereof. The invention as currently presented has a significant advantage over ophthalmic compositions already known in the art. More particularly the present invention relates to a multi-dose ophthalmic aqueous composition comprising a borate, a single polyol and benzalkonium chloride as an antimicrobial agent.
-
公开(公告)号:US20210171602A1
公开(公告)日:2021-06-10
申请号:US17254618
申请日:2019-07-03
发明人: Crystal Mackall , Michael Lin , Robbie Majzner , Hokyung Chung , Louai Labanieh
IPC分类号: C07K14/725 , A61K31/498 , A61K31/426 , C07K16/28 , C12N9/50
摘要: Provided are polypeptides that include, from N-terminus to C-terminus, a chimeric antigen receptor (CAR), a protease, and a degron, where the polypeptide further includes a cleavage site for the protease disposed between the CAR and the degron. Also provided are cells that include such polypeptides (e.g., where the cells express the CAR on their surface) and pharmaceutical compositions including such cells. Nucleic acids that encode the polypeptides, cells including such nucleic acids, and pharmaceutical compositions including such cells, are also provided. Also provided are methods for controlling the expression of a CAR on the surface of a cell, and methods of using the cells of the present disclosure, including methods of using such cells to administer a regulatable CAR cell-based therapy (e.g., a regulatable CAR T cell therapy) to an individual.
-
公开(公告)号:US10980804B2
公开(公告)日:2021-04-20
申请号:US14761518
申请日:2014-01-17
发明人: Siraj Mahamed Ali , Matthew J. Hawryluk , Jie He , Doron Lipson , Vincent A. Miller , Jeffrey S. Ross , Philip James Stephens
IPC分类号: A61K31/517 , A61K31/498 , A61K31/19 , A61K31/5025 , C12N9/12 , A61K31/4412 , A61K45/06 , A61K31/47 , A61K31/435 , A61K31/506 , A61K31/519 , A61K31/4439 , A61K31/53 , A61K31/404 , A61K31/5383 , A61K31/496 , C12Q1/6886 , A61K31/553 , C07K14/705 , C07K14/71 , C07K16/40 , C12N15/113 , C12Q1/6883 , G01N33/573
摘要: Methods and compositions for treating cholangiocarcinoma.
-
公开(公告)号:US10973830B2
公开(公告)日:2021-04-13
申请号:US16372080
申请日:2019-04-01
发明人: John Patrick Maxwell , Paul S. Charifson , Qing Tang , Steven M. Ronkin , Katrina Lee Jackson , Albert Charles Pierce , David J. Lauffer , Pan Li , Simon Giroux , Jinwang Xu , Kevin Michael Cottrell , Mark A. Morris , Nathan D. Waal , John J. Court , Wenxin Gu , Hongbo Deng
IPC分类号: A61K31/498 , C07D241/44 , A61K31/5377 , C07D513/04 , A61K31/506 , A61K31/5386 , C07D241/40 , C07D401/14 , C07D403/12 , C07D403/14 , C07D405/12 , C07D405/14 , C07D413/12 , C07D417/12 , C07D471/04 , C07D473/40 , C07D475/00 , C07D487/04 , C07D491/048 , C07D498/08 , C07D413/04 , C07D491/052 , C07D241/42 , C07D271/12 , C07D401/12 , C07D413/14 , C07D491/056 , C07D491/08
摘要: The present invention relates to Provided are compounds of Formula (I): wherein R1, R2, X, Ring A, Ring B, and Ring C are as defined herein. Compounds of Formula (I) are useful as inhibitors of DNA-PK. Also provided are pharmaceutical compositions comprising said compounds and methods of using the compounds and compositions in the treatment of various diseases, conditions, and disorders.
-
公开(公告)号:US20210070752A1
公开(公告)日:2021-03-11
申请号:US16904890
申请日:2020-06-18
发明人: Joseph ARNDT , Timothy R. CHAN , Kevin GUCKIAN , Gnanasambandam KUMARAVEL , Wen-Cherng LEE , Edward Yin-Shiang LIN , Daniel SCOTT , Lihong SUN , Jermaine THOMAS , Kurt VAN VLOTEN , Deping WANG , Lei ZHANG , Daniel ERLANSON
IPC分类号: C07D471/04 , C07D213/82 , C07D213/85 , C07D241/26 , C07D401/12 , C07D401/14 , C07D403/12 , C07D403/14 , C07D405/14 , C07D409/04 , C07D409/14 , C07D417/14 , C07D473/34 , C07D487/04 , C07D491/052 , C07D519/00 , C07D241/28 , C07D498/04 , A61K31/437 , A61K31/4439 , A61K31/444 , A61K31/452 , A61K31/4725 , A61K31/496 , A61K31/497 , A61K31/498 , A61K31/4985 , A61K31/517 , A61K31/519 , A61K31/53 , A61K31/5377 , A61K31/5383
摘要: The present invention provides compounds useful as inhibitors of PDK1. The present invention also provides compositions thereof, and methods of treating PDK1-mediated diseases.
-
公开(公告)号:US20210015661A1
公开(公告)日:2021-01-21
申请号:US17062863
申请日:2020-10-05
申请人: Allergan, Inc.
发明人: Sai Shankar
IPC分类号: A61F9/00 , A61J1/14 , A61K38/13 , A61K31/5377 , A61K31/573 , A61K31/205 , A61K31/407 , A61K31/496 , A61K31/498 , A61K31/5575
摘要: A container-closure system includes a container configured to hold a therapeutic liquid and having a dispensing tip configured to dispense a dose of the therapeutic liquid. A vented cap is configured to fit over at least a portion of the container including the dispensing tip and having one or more vents that allow air to pass into and out of a cavity defined between the vented cap and the dispensing tip. A second cap is configured to fit over at least a portion of the vented cap. A tamper evident seal is coupled to the second cap and one or both of the container and the vented cap.
-
公开(公告)号:US10857144B2
公开(公告)日:2020-12-08
申请号:US16408931
申请日:2019-05-10
申请人: Bow River LLC
发明人: Sundar Srinivasan , Christina Chow
IPC分类号: A61K31/4468 , A61K31/4995 , A61K31/454 , A61K31/519 , A61K31/4745 , A61K31/397 , A61K31/498 , A61K31/497 , A61K31/5395 , A61K31/506 , A61K31/407 , A61P35/04 , A61P35/02 , A61K9/00 , A61K9/08 , A61K31/5383 , A61P25/18 , A61P25/16 , A61K9/20 , A61K9/48 , A61K31/00 , A61K9/10
摘要: The present disclosure provides for methods of treating a patient with a CYP3A4 substrate drug, wherein the patient is treated with posaconazole. In some embodiments, the patient stops posaconazole treatment, waits for at least 2 days, and then is treated with the CYP3A4 substrate drug as soon as it is safe to do so. In some embodiments, treatment with the CYP3A4 substrate drug is delayed for about 2-42 days after stopping posaconazole. In some embodiments, the patient is treated with a reduced dose of the CYP3A4 substrate drug for about 2-42 days.
-
公开(公告)号:US10829468B2
公开(公告)日:2020-11-10
申请号:US16892661
申请日:2020-06-04
申请人: Neoculi Pty Ltd.
IPC分类号: C07D333/58 , C07C211/29 , C07C281/18 , A61K31/155 , A61K31/341 , A61K31/404 , A61K31/4045 , A61K31/496 , A61K31/498 , A61K31/381 , C07D239/50 , C07D295/135 , A61K31/17 , A61K31/4192 , A61K31/44 , C07C47/565 , C07C251/24 , C07D209/14 , C07D239/48 , C07D241/20 , C07D249/14 , C07D251/54 , C07D307/56 , C07D311/58 , C07D401/14 , A61K9/00 , A61K31/505 , A61K45/06 , C07C335/40 , C07D209/08
摘要: The invention provides compounds of Formula (I), and their use in methods for treating or preventing a protozoan infection in a subject using a compound of Formula (I). The invention also provides the use of a compound of Formula (I) in the manufacture of a medicament for the treatment of a protozoan infection in a subject. The invention further provides a medical device when used in a method of treating or preventing a protozoan infection in a subject and to a medical device comprising the composition of the invention.
-
公开(公告)号:US20200330460A1
公开(公告)日:2020-10-22
申请号:US16643069
申请日:2018-08-30
申请人: AbbVie Inc.
发明人: Christine Collins , Emily O. Dumas , Bo Fu , Abhishek Gulati , Yiran Bonnie Hu , Jens Kort , Matthew Kosloski , Preethi Krishnan , Yang Lei , Chih-Wei Lin , Ran Liu , Frederico Mensa , Iok Chan Ng , Tami Pilot-Matias , David Pugatch , Susan Rhee , Nancy S. Shulman , Roger Trinh , Rolando M. Viani , Stanley Wang , Zhenzhan Zhang
IPC分类号: A61K31/4985 , A61K31/454 , A61K31/7072 , A61K31/498
摘要: The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents to a subject with HCV infection, wherein the treatment lasts for 12 weeks and does not include administration of either interferon or ribavirin, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof.
-
100.
公开(公告)号:US20200316032A1
公开(公告)日:2020-10-08
申请号:US16652909
申请日:2018-10-03
IPC分类号: A61K31/427 , A61K31/352 , A61K31/05 , A61K31/085 , A61K31/5377 , A61K31/167 , A61K31/4155 , A61K31/496 , A61K31/4245 , A61K31/422 , A61K31/498 , A61K31/4196
摘要: There are provided inter alia compounds capable of inhibiting retinal pigment epithelium (RPE) degeneration or geography atrophy (GA) associated with age-related macular degeneration (AMD), and methods of using the same.
-
-
-
-
-
-
-
-
-